Literature DB >> 2305177

Effect of bismuth subsalicylate on Clostridium difficile colitis in hamsters.

T W Chang1, M Y Dong, S L Gorbach.   

Abstract

The therapeutic effect of bismuth subsalicylate (BSS, Pepto-Bismol) in Clostridium difficile colitis was studied in golden Syrian hamsters. C. difficile was fed to the hamsters by orogastric intubation 2-3 days after their arrival. Clindamycin (1.5 mg per animal) was given intraperitoneally 4 days later. Twenty-four hours after challenge with clindamycin, animals were given BSS at dosages of 5, 10, and 15 mg twice daily for 5 days by orogastric intubation. Controls included untreated animals and those given 5 mg of vancomycin once daily by intubation. Delay in the time of death was observed in all BSS-treated animals and was statistically significant on days 4-6 in those receiving 15 mg twice daily. Vancomycin produced a greater delay in death than did BSS. Our study suggests that BSS at a dosage of 15 mg twice daily has some therapeutic effect on C. difficile colitis in hamsters.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2305177     DOI: 10.1093/clinids/12.supplement_1.s57

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  4 in total

1.  Interaction of bismuth subsalicylate with fruit juices, ascorbic acid, and thiol-containing substrates to produce soluble bismuth products active against Clostridium difficile.

Authors:  D E Mahony; A Woods; M D Eelman; N Burford; S J O Veldhuyzen van Zanten
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 2.  Models for the study of Clostridium difficile infection.

Authors:  Emma L Best; Jane Freeman; Mark H Wilcox
Journal:  Gut Microbes       Date:  2012-03-01

3.  Antimicrobial activities of synthetic bismuth compounds against Clostridium difficile.

Authors:  D E Mahony; S Lim-Morrison; L Bryden; G Faulkner; P S Hoffman; L Agocs; G G Briand; N Burford; H Maguire
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

Review 4.  Current and potential applications of bismuth-based drugs.

Authors:  Donal M Keogan; Darren M Griffith
Journal:  Molecules       Date:  2014-09-23       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.